
Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

January 25, 2016

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of
India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: NEULANLAB
Series: EQ

Dear Sirs,

Results Release and Earnings Call Notice

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q3 FY 2016 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary



NEULAND LABORATORIES LIMITED

Neuland's Q3 FY 16 Results Conference Call at 4.30 pm IST on February 3,2016

Hyderabad, January 25, 2016 – Neuland Laboratories Ltd., (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in close to 80 countries, will announce results for the third quarter ending December 2015, financial year ending March 31, 2016 after the Board meeting on February 3, 2016. Following the announcement, the management of the Company will host **earnings call** to discuss the Company's financial performance as per the details below.

Earnings Call Details:

Date	Wednesday 3rd February, 2016
Time	4:30PM to 5:30PM
Conference Dial-in Numbers	
Primary Number	+91 22 3960 0644
Secondary Number	+91 22 6746 4144
<u>Add to Calendar Pre- Register for Pass</u>	
<i>The numbers listed above are universally accessible from all networks and all countries</i>	
Local Access Numbers	6000 1221 (Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada. Accessible from all major carriers except BSNL/MTNL.) 3940 3977 (Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers)
Toll Free Numbers	Hong Kong: 800 964 448 Singapore: 800 101 2045 UK: 0 808 101 1573 USA: 1 866 746 2133
Neuland Participants	Mr. Davuluri Sucheth Rao, Whole Time Director & CEO Mr. Davuluri Saharsh Rao, Whole Time Director & President of Contract Research Mr. Anil Kumar, CFO

Participants are requested to log in 10 minutes prior to the start of the scheduled call.



NEULAND LABORATORIES LIMITED

About Neuland Labs

For over 30 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 48 U.S. drug master files (DMFs) and a total of around 400 DMFs in the European Union (EU) and other countries. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, Anvisa (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

For further information, please contact:

Arpita Poola Corp Planning and Communication, Neuland Labs Ph: +91 40 3021 1600 Email: arpita@neulandlabs.com	Ankit Gupta Christensen Investor Relations Ph: +91 22 4215 0210 Email: ankitgupta@christensenir.com
---	---

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Neuland and its subsidiaries/ associates. There can be no assurance that future developments affecting Neuland and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Neuland does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.